Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

AD Staniszewska, D Pilger, SJ Gill, K Jamal… - Clinical Cancer …, 2024 - AACR
Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB)
penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in …
被引用次数：6 相关文章

Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.

AD Staniszewska, D Pilger, SJ Gill, K Jamal… - … Cancer Research: an …, 2023 - europepmc.org
We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant
selective inhibitor of PARP1 and assessed its efficacy and safety alone and in combination …

Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1

AD Staniszewska, D Pilger, SJ Gill… - … : an official journal …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB)
penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in …

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

AD Staniszewska, D Pilger, SJ Gill, K Jamal… - Clinical Cancer …, 2024 - AACR
Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB)
penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in …